# Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

> **NCT03107962** · PHASE2 · UNKNOWN · sponsor: **Mingzhi Zhang** · enrollment: 20 (estimated)

## Conditions studied

- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

## Interventions

- **DRUG:** Pembrolizumab (PD-1 Blocking Antibody)

## Key facts

- **NCT ID:** NCT03107962
- **Lead sponsor:** Mingzhi Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-19
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03107962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03107962, "Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03107962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*